Advertisement

The Non-compliant Psoriasis Patient

  • Kevin K. Wu
  • Michael P. Lee
  • Jashin J. Wu
Chapter
Part of the Clinical Cases in Dermatology book series (CLIDADE)

Abstract

Patient compliance refers to the following of treatment instructions set forth by the clinician. Compliance may be maximized by choosing therapies with less frequent application, quicker onset of action, and fewer perceived side-effects. Psoriasis treatments with the highest compliance include biologics with longer dosing intervals, such as ustekinumab. Psoriasis treatments with the lowest compliance include topical therapies.

Keywords

Compliance Psoriasis Ustekinumab Tildrakizumab Guselkumab Secukinumab Ixekizumab Topical corticosteroid 

References

  1. 1.
    Richards HL, Fortune DG, O’Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41(4):581–3.PubMedGoogle Scholar
  2. 2.
    Svendsen MT, Andersen F, Hansen J, Johannessen H, Andersen KE. Medical adherence to topical corticosteroid preparations prescribed for psoriasis: a systematic review. J Dermatolog Treat. 2017;28(1):32–9.  https://doi.org/10.1080/09546634.2016.1178375.CrossRefPubMedGoogle Scholar
  3. 3.
    Menter MA, Armstrong AW, Gordon KB, Wu JJ. Common and not-so-common comorbidities of psoriasis. Semin Cutan Med Surg. 2018;37(2S):S48–51.  https://doi.org/10.12788/j.sder.2018.011.CrossRefPubMedGoogle Scholar
  4. 4.
    Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–5.  https://doi.org/10.1001/archdermatol.2010.186.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rapp SR, Exum ML, Reboussin DM, Feldman SR, Fleischer A, Clark A. The physical, psychological and social impact of psoriasis. J Health Psychol. 1997;2(4):525–37.  https://doi.org/10.1177/135910539700200409.CrossRefPubMedGoogle Scholar
  6. 6.
    Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457–65.  https://doi.org/10.1016/j.jaad.2009.09.014.CrossRefPubMedGoogle Scholar
  7. 7.
    Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010;62(5):812–8.  https://doi.org/10.1016/j.jaad.2009.07.022.CrossRefPubMedGoogle Scholar
  8. 8.
    Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, et al. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial. Circ Cardiovasc Imaging. 2018;11(6):e007394.  https://doi.org/10.1161/CIRCIMAGING.117.007394.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Guerin A, Singh R, Ganguli A. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus phototherapy: an observational cohort study. J Am Acad Dermatol. 2018;79(1):60–8.  https://doi.org/10.1016/j.jaad.2018.02.050.CrossRefPubMedGoogle Scholar
  10. 10.
    Choi CW, Kim BR, Ohn J, Youn SW. The advantage of cyclosporine a and methotrexate rotational therapy in long-term systemic treatment for chronic plaque psoriasis in a real world practice. Ann Dermatol. 2017;29(1):55–60.  https://doi.org/10.5021/ad.2017.29.1.55.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Gokdemir G, Ari S, Koslu A. Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol. 2008;22(3):330–5.  https://doi.org/10.1111/j.1468-3083.2007.02425.x.CrossRefPubMedGoogle Scholar
  12. 12.
    Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408–14.  https://doi.org/10.1001/archderm.140.4.408.CrossRefPubMedGoogle Scholar
  13. 13.
    Zalewska A, Miniszewska J, Chodkiewicz J, Narbutt J. Acceptance of chronic illness in psoriasis vulgaris patients. J Eur Acad Dermatol Venereol. 2007;21(2):235–42.  https://doi.org/10.1111/j.1468-3083.2006.01912.x.CrossRefPubMedGoogle Scholar
  14. 14.
    Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55(4):607–13.  https://doi.org/10.1016/j.jaad.2005.12.021.CrossRefPubMedGoogle Scholar
  15. 15.
    Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.  https://doi.org/10.1186/1477-7525-2-12.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Uhlenhake EE, Kurkowski D, Feldman SR. Conversations on psoriasis—what patients want and what physicians can provide: a qualitative look at patient and physician expectations. J Dermatolog Treat. 2010;21(1):6–12.  https://doi.org/10.3109/09546630903085328.CrossRefPubMedGoogle Scholar
  17. 17.
    Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19(Suppl 3):2–6.  https://doi.org/10.1111/j.1468-3083.2005.01329.x.CrossRefPubMedGoogle Scholar
  18. 18.
    Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222(4):363–74.  https://doi.org/10.1159/000329026.CrossRefPubMedGoogle Scholar
  19. 19.
    Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther. 2015;32(11):983–1028.  https://doi.org/10.1007/s12325-015-0256-7.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Clemmensen A, Spon M, Skov L, Zachariae C, Gniadecki R. Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2011;25(9):1037–40.  https://doi.org/10.1111/j.1468-3083.2010.03914.x.CrossRefPubMedGoogle Scholar
  21. 21.
    Umezawa Y, Nobeyama Y, Hayashi M, Fukuchi O, Ito T, Saeki H, Nakagawa H. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 2013;40(12):1008–13.  https://doi.org/10.1111/1346-8138.12353.CrossRefPubMedGoogle Scholar
  22. 22.
    Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F, et al. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169(3):666–72.  https://doi.org/10.1111/bjd.12422.CrossRefPubMedGoogle Scholar
  23. 23.
    Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091–6.  https://doi.org/10.1111/j.1365-2133.2011.10213.x.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Kevin K. Wu
    • 1
  • Michael P. Lee
    • 2
  • Jashin J. Wu
    • 3
  1. 1.Frank H. Netter MD School of Medicine at Quinnipiac UniversityNorth HavenUSA
  2. 2.Eastern Virginia Medical SchoolNorfolkUSA
  3. 3.Founder and CEODermatology Research and Education FoundationIrvineUSA

Personalised recommendations